Literature DB >> 8289476

Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.

A Gotoh1, K Miyazawa, K Ohyashiki, K Toyama.   

Abstract

Constitutive activation of BCR-ABL tyrosine kinase fusion protein has been shown to be an essential step in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemias. We studied the tyrosine phosphorylated proteins which might be involved in the signaling pathway p185BCR-ABL using a Ph-positive acute lymphoblastic leukemia cell line. p185BCR-ABL but not p145c-abl was constitutively phosphorylated on tyrosine in this cell line. p21ras GTPase-activating protein (GAP) was physically associated with p185BCR-ABL, but not with p145c-abl, and GAP-associated proteins p62/p190 were found to be tyrosine-phosphorylated. Furthermore, p185BCR-ABL was also physically associated with phospholipase C-gamma 1 (PLC-gamma) and phosphatidylinositol 3'-kinase (P13-kinase). Concomitantly, both PLC-gamma and p85 subunit of P13-kinase are tyrosine-phosphorylated in the cells with p185BCR-ABL. These data suggest that GAP, GAP-associated proteins, PLC-gamma, and P13-kinase may participate in downstream signaling for p185BCR-ABL tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289476

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling.

Authors:  S Lemay; D Davidson; S Latour; A Veillette
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene.

Authors:  Tara Ann Burns; Marimuthu Subathra; Paola Signorelli; Young Choi; Xiaofeng Yang; Yong Wang; Maristella Villani; Kapil Bhalla; Daohong Zhou; Chiara Luberto
Journal:  J Lipid Res       Date:  2012-11-16       Impact factor: 5.922

3.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

4.  TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.

Authors:  D Perrotti; S Bonatti; R Trotta; R Martinez; T Skorski; P Salomoni; E Grassilli; R V Lozzo; D R Cooper; B Calabretta
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

5.  Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.

Authors:  Xian Li; Yuqi Cai; Jillian Goines; Patricia Pastura; Lars Brichta; Adam Lane; Timothy D Le Cras; Elisa Boscolo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

6.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.